Vol. 23 No. 1 (2022)

Published: 2022-02-02

Editorial

The Importance of Real-World Evidence in Understanding Influenza Vaccine Effectiveness

Pietro Ferrara, Lorenzo Giovanni Mantovani
- HTML
- PDF

Original research

Cost-effectiveness of Empagliflozin, in Addition to Metformin, in Patients with Type 2 Diabetes in Italy

Edoardo Mannucci, Gianni Ghetti
- HTML
- PDF
[Budget Impact Analysis of the Adjuvanted Quadrivalent Influenza Vaccine in the Elderly in Italy]

Vincenzo Baldo, Marco Bellone
- HTML
- PDF
[Cost-Utility Analysis of Dupilumab for the Treatment of Severe Atopic Dermatitis in Children and Adolescents in Italy]

Elena Galli, Maria Paola Pedone, Miryana Dobreva, Rossella Bitonti, Roberta Di Turi
- HTML
- PDF
Economic Consequences of Administering Obinutuzumab as a Short Duration Infusion in Italian Patients with Advanced Follicular Lymphoma: A Cost Analysis

Marco Bellone, Lorenzo Pradelli, Rita Tavarozzi, Marco Ladetto, Giuliana Nepoti, Emanuele Guardalben, Daniela Ghislieri
- HTML
- PDF
Artificial Urinary Sphincters as a Treatment for Post-Prostatectomy Severe Urinary Incontinence in Italy: A Cost-Utility Analysis

Francesco Mennini, Daniele Rossi, Andrea Marcellusi
- HTML
- PDF
Cost-Effectiveness of Dimethyl Fumarate Compared to Teriflunomide for Relapsing Remitting Multiple Sclerosis Patients in Italy

Lorenzo Giovanni Mantovani, Paolo Angelo Cortesi, Alessandra Cardillo, Laura Santoni, Luca Prosperini
- HTML
- PDF
Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy

Patrizia Berto, Marco Bellone, Alice Sabinot, Carmine Pinto, Massimo Martino, Daniele Generali, Pier Luigi Carriero, Maria Domenica Sanna
- HTML
- PDF